Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ANTXR2 | P58335 | 2/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23871835 | 1.00 | CYP2D6 (0.39) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL22072486 | 1.00 | CYP2D6 (0.39) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL23871867 | 1.00 | CYP2D6 (0.39) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL23871937 | 0.96 | CYP2D6 (0.38) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL23855307 | 0.96 | CYP2D6 (0.38) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL22033976 | 0.95 | CYP2D6 (0.42) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL22033879 | 0.95 | CYP2D6 (0.42) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL22033947 | 0.95 | CYP2D6 (0.42) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL22033952 | 0.95 | CYP2D6 (0.42) | CYP2D6THRBHSD17B10MAPTCA2 | |
| SCHEMBL23855304 | 0.91 | CYP2D6 (0.40) | CYP2D6THRBHSD17B10MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113490489-A | Monomethyl fumarate-carrier conjugates and methods of use thereof | 旗舰创业创新五公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299079-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | SLC16A1, SLC16A3, SLC16A8 | CYP2D6 650/4885THRB 3830/4885HSD17B10 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.